Search

Your search keyword '"Van Laere, K."' showing total 816 results
Start Over Author "Van Laere, K."
816 results on '"Van Laere, K."'

5. A high-quality genome sequence of Rosa chinensis to elucidate ornamental traits

Author

Hibrand Saint-Oyant, L., Ruttink, T., Hamama, L., Kirov, I., Lakhwani, D., Zhou, N. N., Bourke, P. M., Daccord, N., Leus, L., Schulz, D., Van de Geest, H., Hesselink, T., Van Laere, K., Debray, K., Balzergue, S., Thouroude, T., Chastellier, A., Jeauffre, J., Voisine, L., Gaillard, S., Borm, T. J. A., Arens, P., Voorrips, R. E., Maliepaard, C., Neu, E., Linde, M., Le Paslier, M. C., Bérard, A., Bounon, R., Clotault, J., Choisne, N., Quesneville, H., Kawamura, K., Aubourg, S., Sakr, S., Smulders, M. J. M., Schijlen, E., Bucher, E., Debener, T., De Riek, J., and Foucher, F.

Published
2018
Full Text
View/download PDF

8. Correction: Neuroinflammation and its association with cognition, neuronal markers and peripheral inflammation after chemotherapy for breast cancer. Cancers 2021, 13, 4198

Author

Schroyen, G., Blommaert, J., van Weehaeghe, D., Sleurs, C., Vandenbulcke, M., Dedoncker, N., Hatse, S., Goris, A., Koole, M., Smeets, A., van Laere, K., Sunaert, S., Deprez, S., Schroyen, G., Blommaert, J., van Weehaeghe, D., Sleurs, C., Vandenbulcke, M., Dedoncker, N., Hatse, S., Goris, A., Koole, M., Smeets, A., van Laere, K., Sunaert, S., and Deprez, S.

Abstract

In the original publication [1], there was a mistake in Figure 2A as published. The upper panel was incorrectly a duplicate version of the lower panel, and included PVC VT values, instead of uncorrected VT values. In the caption, a typo in referring to legend colors (blue instead of red image color) was also observed. The corrected Figure 2 appears below. The accompanying text in the manuscript does not include these mistakes and therefore remains unchanged. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Published
2023

21. A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies

Author

Perani, D, Iaccarino, L, Lammertsma, A, Windhorst, A, Edison, P, Boellaard, R, Hansson, O, Nordberg, A, Jacobs, A, Bottlaender, M, Brooks, D, Carroll, M, Chalon, S, Gee, A, Gerhard, A, Halldin, C, Herholz, K, Herth, M, Hinz, R, Knudsen, G, Kuhnast, B, Lopez-Picon, F, Moresco, R, Pappata, S, Rinne, J, Rodriguez-Vieitez, E, Santiago-Ribeiro, M, Turkheimer, F, Van Laere, K, Varrone, A, Vercouillie, J, Winkeler, A, Perani D., Iaccarino L., Lammertsma A. A., Windhorst A. D., Edison P., Boellaard R., Hansson O., Nordberg A., Jacobs A. H., Bottlaender M., Brooks D., Carroll M. A., Chalon S., Gee A., Gerhard A., Halldin C., Herholz K., Herth M. M., Hinz R., Knudsen G. M., Kuhnast B., Lopez-Picon F., Moresco R. M., Pappata S., Rinne J. O., Rodriguez-Vieitez E., Santiago-Ribeiro M. J., Turkheimer F. E., Van Laere K., Varrone A., Vercouillie J., Winkeler A., Perani, D, Iaccarino, L, Lammertsma, A, Windhorst, A, Edison, P, Boellaard, R, Hansson, O, Nordberg, A, Jacobs, A, Bottlaender, M, Brooks, D, Carroll, M, Chalon, S, Gee, A, Gerhard, A, Halldin, C, Herholz, K, Herth, M, Hinz, R, Knudsen, G, Kuhnast, B, Lopez-Picon, F, Moresco, R, Pappata, S, Rinne, J, Rodriguez-Vieitez, E, Santiago-Ribeiro, M, Turkheimer, F, Van Laere, K, Varrone, A, Vercouillie, J, Winkeler, A, Perani D., Iaccarino L., Lammertsma A. A., Windhorst A. D., Edison P., Boellaard R., Hansson O., Nordberg A., Jacobs A. H., Bottlaender M., Brooks D., Carroll M. A., Chalon S., Gee A., Gerhard A., Halldin C., Herholz K., Herth M. M., Hinz R., Knudsen G. M., Kuhnast B., Lopez-Picon F., Moresco R. M., Pappata S., Rinne J. O., Rodriguez-Vieitez E., Santiago-Ribeiro M. J., Turkheimer F. E., Van Laere K., Varrone A., Vercouillie J., and Winkeler A.

Abstract

Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications.

Published
2019

22. Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies

Author

Perani, D, Iaccarino, L, Jacobs, A, Lammertsma, A, Nordberg, A, Windhorst, A, Gerhard, A, Winkeler, A, Gee, A, Kuhnast, B, Halldin, C, Brooks, D, Rodriguez-Vieitez, E, Turkheimer, F, Lopez-Picon, F, Knudsen, G, Vercouillie, J, Rinne, J, Herholz, K, Van Laere, K, Santiago-Ribeiro, M, Herth, M, Carroll, M, Bottlaender, M, Hansson, O, Edison, P, Hinz, R, Boellaard, R, Moresco, R, Pappata, S, Perani D., Iaccarino L., Jacobs A. H., Lammertsma A. A., Nordberg A., Windhorst A. D., Gerhard A., Winkeler A., Gee A., Kuhnast B., Halldin C., Brooks D., Rodriguez-Vieitez E., Turkheimer F. E., Lopez-Picon F., Knudsen G. M., Vercouillie J., Rinne J. O., Herholz K., Van Laere K., Santiago-Ribeiro M. J., Herth M. M., Carroll M. A., Bottlaender M., Hansson O., Edison P., Hinz R., Boellaard R., Moresco R. M., Pappata S., Perani, D, Iaccarino, L, Jacobs, A, Lammertsma, A, Nordberg, A, Windhorst, A, Gerhard, A, Winkeler, A, Gee, A, Kuhnast, B, Halldin, C, Brooks, D, Rodriguez-Vieitez, E, Turkheimer, F, Lopez-Picon, F, Knudsen, G, Vercouillie, J, Rinne, J, Herholz, K, Van Laere, K, Santiago-Ribeiro, M, Herth, M, Carroll, M, Bottlaender, M, Hansson, O, Edison, P, Hinz, R, Boellaard, R, Moresco, R, Pappata, S, Perani D., Iaccarino L., Jacobs A. H., Lammertsma A. A., Nordberg A., Windhorst A. D., Gerhard A., Winkeler A., Gee A., Kuhnast B., Halldin C., Brooks D., Rodriguez-Vieitez E., Turkheimer F. E., Lopez-Picon F., Knudsen G. M., Vercouillie J., Rinne J. O., Herholz K., Van Laere K., Santiago-Ribeiro M. J., Herth M. M., Carroll M. A., Bottlaender M., Hansson O., Edison P., Hinz R., Boellaard R., Moresco R. M., and Pappata S.

Abstract

Introduction: A rapid transition from a clinical-based classification to a pathology-based classification of neurodegenerative conditions, largely promoted by the increasing availability of imaging biomarkers, is emerging. The Framework for Innovative Multi-tracer molecular Brain Imaging, funded by the EU Joint Program - Neurodegenerative Disease Research 2016 “Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration,” aimed at providing a roadmap for the applications of established and new molecular imaging techniques in dementia. Methods: We consider current and future implications of adopting a pathology-based framework for the use and development of positron emission tomography techniques. Results: This approach will enhance efforts to understand the multifactorial etiology of Alzheimer's disease and other dementias. Discussion: The availability of pathology biomarkers will soon transform clinical and research practice. Crucially, a comprehensive understanding of strengths and caveats of these techniques will promote an informed use to take full advantage of these tools.

Published
2019

23. 1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France

Author

Gabelle, A., Roche, S., Gény, C., Portet, F., Touchon, J., Lehmann, S., De Meyer, G., Shapiro, F., Vanderstichele, H., Vanmechelen, E., Engelborghs, S., De Deyn, P. P., Shaw, L., Trojanowski, J., Nestor, S. M., Rupsingh, R., Borrie, M., Smith, M., Wells, J. L., Bartha, R., Blennow, K., De Meyer, G., Hansson, O., Minthon, L., Wallin, A., Zetterberg, H., Lewezuk, P., Vandertischele, H., Kornhuber, J., Wiltfang, J., Iqbal, K., Chalbot, S., Grundke-Iqbal, I., Gertz, H. J., Berwig, M., Leicht, H., Zhu, C. W., Leibman, C., Townsend, R., Mclaughlin, T., Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Sano, M., Stern, Y., Bravo, G., Dubois, M. F., Hansel, S., Duguet, A. M., Robert, P. H., Deudon, A., Ake, N., Gervais, X., Leone, E., Lavallart, B., Amato, D., Zavitz, K., Green, R. C., Schneider, L. S., Swabb, E., Van Kan, G. Abellan, Carrie, I., Gillette, S., Soto, M. E., Gardette, J., Przybylski, C., Andrieu, S., Vellas, B., Dangour, A. D., Allen, E., Elbourne, D., Fletcher, A., Richards, M., Uauy, R., Green, R. C., Schneider, L. S., Zavitz, K. H., Wurtman, R. J., Peters, O., Lorenz, D., Möller, H. J., Frölich, L., Heuser, I., Vandenberghe, R., Thurfjell, L., Owenius, R., Brooks, D. J., Nelissen, N., Koole, M., Bormans, G., Van Laere, K., Boada, M., Muñoz, J., Tárraga, L., Ortiz, P., Hernández, I., Becker, J., López, O., Buendia, M., Pla, R., Grifols, J. R., Paez, A., Núñez, L., Ferrer, I., Lachno, D. R., De Groote, G., Kostanjevecki, V., Siemers, E. R., Willey, M. B., Ruiz, A., Ramírez-Lorca, R., Sáez, M. E., Mauleón, A., Rosende-Roca, M., Martínez-Lage, P., Gutiérrez, M., Real, L. Miguel, López-arrieta, J., Gayán, J., Antúnez, C., González-Pérez, A., Hugonot-Diener, L., Bchiri, J. El, Fraisse, M. L., Von Raison, F., Bone, M., Duron, E., Husson, J. M., Meeuwsen, E. J., Melis, R. J. F., Adang, E. M., Krabbe, P. F., Schölzel-Dorenbos, C. J. M., Ruckert, M. G. M. Olde, Truemner, J., Best, S., Lozanski, M., Nsiah, C., Wells, J., Tractenberg, R. E., Tractenberg, R. E., Chu, L. W., Yik, P. Y., Mok, W., Chung, C. P., Gauthier, S., Douillet, P., Doody, R., Fox, N. C., Orgogozo, J. M., Ingenbleek, Y., Bienvenu, J., Molloy, D. W., Standish, T., Cowan, D., Almeida, E., Diloreto, P., Woolmore-Goodwin, S., Clarke, J., Berardi, P., Smith, M., Purcell, T., Woolmore-Goodwin, S., Gutmanis, I., Borrie, M., Robert, P. H., Reynish, E., Cantet, C., Erder, M. H., Fillit, H., Hofbauer, R. K., Setyawan, J., Tourkodimitris, S., Fridman, M., Lyketsos, C., Unzeta, M., Valente, T., Hidalgo, J., Ramirez, B., Anglés, N., Morelló, J. R., Reguant, J., Boada, M., Claassen, J. A., Van Beek, A. H., Olde Rikkert, M. G., Roca, I., Cuberas, G., Castell, J., Buendia, M., Pla, R., Núñez, L., Ferrer, I., Latger, C., Tramoni, E., Elkhoury, C., Aubert-Khalfa, S., Ceccaldi, M., Schneeberger, A., Mandler, M., Otava, O., Mattner, F., Schmidt, W., Gatignol, P., David, C., Guitton, C., Plaza, M., Szaniszlo, P., German, P., Hajas, G., Kruzel, M., Boldogh, I., Wesnes, K., Satek, S., Turk, P., Satek, S., Vinay, M., Wetten, S., Li, H., Galwey, N., Gibson, R. A., Irizarry, M. C., Nourhashémi, F., Gillette-Guyonnet, S., Andrieu, S., Rolland, Y., Ousset, P. J., Verwey, N. A., Blennow, K., Clark, C., Cole, G. M., De Deyn, P. P., Galasko, D., Hampel, H., Hartmann, T., Kapaki, E., Lannfelt, L., Mehta, P. D., Parnetti, L., Petzold, A., Pirttila, T., Saleh, L., Skinningsrud, A., Swieten, J. C. V., Verbeek, M. M., Wiltfang, J., Younkin, S., Blankenstein, M. A., Ishihara-Paul, L., Viswanathan, A., Allen, J. K., Hyman, B. T., Betensky, R., Weil, J., The Alzheimer’s Disease Neuroimaging Initiative, The MAPT Study Investigators, The Xaliproden Ad Study Team, and the PLASA Group

Published
2008
Full Text
View/download PDF

24. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Author

Sanchez-Felipe, L, Vercruysse, T, Sharma, S, Ma, J, Lemmens, V, Van Looveren, D, Arkalagud Javarappa, MP, Boudewijns, R, Malengier-Devlies, B, Liesenborghs, L, Kaptein, SJF, De Keyzer, C, Bervoets, L, Debaveye, S, Rasulova, M, Seldeslachts, L, Li, LH, Jansen, S, Yakass, MB, Verstrepen, BE, Böszörményi, KP, Kiemenyi-Kayere, G, van Driel, N, Quaye, O, Zhang, X, Horst, S, Mishra, N, Deboutte, W, Matthijnssens, J, Coelmont, L, Vandermeulen, C, Heylen, E, Vergote, V, Schols, D, Wang, Zhongde, Bogers, W, Kuiken, Thijs, Verschoor, E, Cawthorne, C, Van Laere, K, Opdenakker, G, Velde, G, Weynand, B, Teuwen, DE, Matthys, P, Neyts, J, Jan Thibaut, H, Dallmeier, K, Sanchez-Felipe, L, Vercruysse, T, Sharma, S, Ma, J, Lemmens, V, Van Looveren, D, Arkalagud Javarappa, MP, Boudewijns, R, Malengier-Devlies, B, Liesenborghs, L, Kaptein, SJF, De Keyzer, C, Bervoets, L, Debaveye, S, Rasulova, M, Seldeslachts, L, Li, LH, Jansen, S, Yakass, MB, Verstrepen, BE, Böszörményi, KP, Kiemenyi-Kayere, G, van Driel, N, Quaye, O, Zhang, X, Horst, S, Mishra, N, Deboutte, W, Matthijnssens, J, Coelmont, L, Vandermeulen, C, Heylen, E, Vergote, V, Schols, D, Wang, Zhongde, Bogers, W, Kuiken, Thijs, Verschoor, E, Cawthorne, C, Van Laere, K, Opdenakker, G, Velde, G, Weynand, B, Teuwen, DE, Matthys, P, Neyts, J, Jan Thibaut, H, and Dallmeier, K

Abstract

The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response1. Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. YF-S0 has an excellent safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and—concomitantly—protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profiled in mice. In a hamster model2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.

Published
2021

25. An optimized MRI and PET based clinical protocol for improving the differential diagnosis of geriatric depression and Alzheimer's disease

Author

Van Laere K, Mathieu Vandenbulcke, Heleen Vanhaute, Rik Vandenberghe, Louise Emsell, Kristof Vansteelandt, Stefan Sunaert, Filip Bouckaert, Christiaens D, Van den Stock J, and De Winter F

Subjects
Oncology, NATIONAL INSTITUTE, medicine.medical_specialty, Amyloid, MILD COGNITIVE IMPAIRMENT, Clinical Neurology, LATE-LIFE DEPRESSION, Neuroscience (miscellaneous), Amyloid pet, Neuroimaging, Disease, Hippocampus, RECOMMENDATIONS, HIPPOCAMPAL ATROPHY, Diagnosis, Differential, Text mining, Clinical Protocols, Alzheimer Disease, Internal medicine, medicine, Humans, CRITERIA, Radiology, Nuclear Medicine and imaging, Depression (differential diagnoses), Aged, Psychiatry, 18-F Flutemetamol, Aniline Compounds, Science & Technology, business.industry, Depression, DEMENTIA, Biomarker, Classification, Magnetic Resonance Imaging, AMYLOID PET, Psychiatry and Mental health, Clinical diagnosis, Positron-Emission Tomography, Hippocampal volume, Neurosciences & Neurology, PITUITARY-ADRENAL AXIS, Differential diagnosis, business, ASSOCIATION WORKGROUPS, Life Sciences & Biomedicine
Abstract

OBJECTIVEMRI derived hippocampal volume (HV) and amyloid PET may be useful clinical biomarkers for differentiating between geriatric depression and Alzheimer’s Disease (AD). Here we investigated the incremental value of HV and 18F-flutemetmol PET in tandem and sequentially to improve discrimination in unclassified participants.METHODTwo approaches were compared in 41 participants with geriatric depression and 27 participants with probable AD: (1) amyloid and HV combined in one model and (2) HV first and then amyloid.RESULTSBoth HV(χ2(1) = 6.46: p= 0.011) and amyloid (χ2(1) =11.03: p=0.0009) were significant diagnostic predictors of depression (sensitivity: 95%, specificity: 89%). (2) 51% of participants were correctly classified according to clinical diagnosis based on HV alone, increasing to 87% when adding amyloid data (sensitivity: 94%, specificity: 78%).CONCLUSIONHippocampal volume may be a useful gatekeeper for identifying depressed individuals at risk for AD who would benefit from additional amyloid biomarkers when available.

Published
2022
Full Text
View/download PDF

27. Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006

Author

Pritchett, Y., McCarberg, B., Watkin, J., Chappell, A., Robinson, M., Xu, J., Rotz, B., Wernicke, J., Detke, M., Iyengar, S., Henck, J., Bymaster, F., Callaghan, J., Knadler, M., Thase, M., Meratee, M., Chung, J., Schweitzer, J., Byrnes, K., Stoica, B., Di Giovanni, S., De Biase, A., Knoblach, S., Hoffman, E., Faden, A., Michaeli, S., Sorce, D., Öz, G., Ugurbil, K., Garwood, M., Tuite, P., Jett, D., Deberdt, W., Csernansky, J., Buckley, P., Peiskens, J., Lipkovich, I., Kollack-Walter, S., Houston, J., Zhang, Y., Liu-Siefert, H., Buckley, P. F., Csernansky, J. G., Peuskens, J., Kollack-Walker, S., Houston, J. P., Rotelli, M., Theodore, W., Giovacchini, G., Bagic, A., Herscovitch, P., Carson, R., Herholz, K., Weisenbach, S., Hilker, R., Heiss, W., Nahab, F., Hallett, M., El-Khodor, B., Edgar, N., Chen, A., Heyes, M. P., Jiang, Q., Ahmed, S., Pedersen, R., Musgnung, J., Entsuah, R., Nordberg, A., Masdeu, J., Gerhard, A., Ebmeier, K., Pappata, S., Perani, D., van Laere, K., Halldin, C., Salmon, E., Knudsen, G., Robins, S., Fehlings, M., Baptiste, D., Skolnick, B. E., Davis, S. M., Bran, N. C., Mathew, S. E., Mayer, S. A., Kaminski, R. M., Marini, H., Ortinski, P. I., Yonekawa, W., Vicini, S., Rogawski, M. A., Gasior, M., Tang, R., and White, N.

Published
2006
Full Text
View/download PDF

50. Passive detector for measurement of the implanted 210Po activity in glass

Author

Meesen, G., Uyttenhove, J., Poffijn, A., Van Laere, K., and Buysse, J.

Subjects
Solar energy -- Passive systems, Atmospheric radon -- Measurement, Business, Electronics, Electronics and electrical industries
Abstract

It is a well known fact that radon is the most important factor in the natural radiation background. For complete dose calculations we need information about the radon concentration up to 25 years ago. As suggested by C. Samuelsson et al. in 1988, the activity of the implanted radon daughter 210Po can be used to reconstruct the radon activity over the past decades. For large scale surveys in dwellings a passive detector based on polycarbonate foils has been investigated. This system has a sufficient sensitivity to detect 210Po levels down to 1 Bq/[m.sup.2] with a 6 month measuring period.

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results